Pfizer Inc. Logo

Pfizer Inc.

PFE.F

(2.8)
Stock Price

27,04 EUR

-3% ROA

-2.84% ROE

-63.8x PER

Market Cap.

165.551.241.958,44 EUR

78.31% DER

5.72% Yield

-4.66% NPM

Pfizer Inc. Stock Analysis

Pfizer Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Pfizer Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (22.82%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (35%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

5 PBV

The stock's PBV ratio (1.67x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

6 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

7 Buffet Intrinsic Value

The company's stock seems undervalued (107) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

11 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Pfizer Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Pfizer Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Pfizer Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Pfizer Inc. Revenue
Year Revenue Growth
1985 4.024.500.000
1986 4.476.000.000 10.09%
1987 4.919.800.000 9.02%
1988 5.385.400.000 8.65%
1989 5.671.500.000 5.04%
1990 6.406.000.000 11.47%
1991 6.950.000.000 7.83%
1992 7.230.200.000 3.88%
1993 7.477.700.000 3.31%
1994 8.281.300.000 9.7%
1995 10.021.400.000 17.36%
1996 11.306.000.000 11.36%
1997 12.504.000.000 9.58%
1998 13.544.000.000 7.68%
1999 16.204.000.000 16.42%
2000 29.574.000.000 45.21%
2001 32.259.000.000 8.32%
2002 32.373.000.000 0.35%
2003 45.188.000.000 28.36%
2004 52.516.000.000 13.95%
2005 51.298.000.000 -2.37%
2006 48.371.000.000 -6.05%
2007 48.418.000.000 0.1%
2008 48.296.000.000 -0.25%
2009 50.009.000.000 3.43%
2010 67.809.000.000 26.25%
2011 67.425.000.000 -0.57%
2012 58.986.000.000 -14.31%
2013 51.584.000.000 -14.35%
2014 49.605.000.000 -3.99%
2015 48.851.000.000 -1.54%
2016 52.824.000.000 7.52%
2017 52.546.000.000 -0.53%
2018 53.647.000.000 2.05%
2019 51.750.000.000 -3.67%
2020 41.908.000.000 -23.48%
2021 81.288.000.000 48.45%
2022 100.330.000.000 18.98%
2023 52.928.000.000 -89.56%
2023 58.496.000.000 9.52%
2024 53.132.000.000 -10.1%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Pfizer Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 1.567.000.000 100%
1997 1.928.000.000 18.72%
1998 2.279.000.000 15.4%
1999 2.776.000.000 17.9%
2000 4.435.000.000 37.41%
2001 4.847.000.000 8.5%
2002 5.176.000.000 6.36%
2003 7.131.000.000 27.42%
2004 7.684.000.000 7.2%
2005 7.442.000.000 -3.25%
2006 7.599.000.000 2.07%
2007 8.089.000.000 6.06%
2008 7.945.000.000 -1.81%
2009 7.845.000.000 -1.27%
2010 9.413.000.000 16.66%
2011 9.112.000.000 -3.3%
2012 7.870.000.000 -15.78%
2013 6.678.000.000 -17.85%
2014 8.393.000.000 20.43%
2015 7.690.000.000 -9.14%
2016 7.872.000.000 2.31%
2017 7.657.000.000 -2.81%
2018 8.006.000.000 4.36%
2019 8.650.000.000 7.45%
2020 9.405.000.000 8.03%
2021 13.829.000.000 31.99%
2022 11.428.000.000 -21.01%
2023 10.844.000.000 -5.39%
2023 10.679.000.000 -1.55%
2024 10.784.000.000 0.97%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Pfizer Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 11.355.000.000 100%
2014 10.997.000.000 -3.26%
2015 11.709.000.000 6.08%
2016 11.637.000.000 -0.62%
2017 11.684.000.000 0.4%
2018 11.755.000.000 0.6%
2019 12.050.000.000 2.45%
2020 9.815.000.000 -22.77%
2021 10.703.000.000 8.3%
2022 10.877.000.000 1.6%
2023 0 0%
2023 11.071.000.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Pfizer Inc. EBITDA
Year EBITDA Growth
1985 929.700.000
1986 1.046.100.000 11.13%
1987 969.400.000 -7.91%
1988 1.032.000.000 6.07%
1989 1.101.000.000 6.27%
1990 1.096.600.000 -0.4%
1991 1.677.300.000 34.62%
1992 1.512.500.000 -10.9%
1993 1.126.900.000 -34.22%
1994 2.375.500.000 52.56%
1995 3.195.200.000 25.65%
1996 3.786.000.000 15.6%
1997 4.106.000.000 7.79%
1998 5.101.000.000 19.51%
1999 5.192.000.000 1.75%
2000 12.699.000.000 59.11%
2001 12.964.000.000 2.04%
2002 13.927.000.000 6.91%
2003 22.491.000.000 38.08%
2004 25.133.000.000 10.51%
2005 24.161.000.000 -4.02%
2006 21.266.000.000 -13.61%
2007 17.693.000.000 -20.19%
2008 26.236.000.000 32.56%
2009 22.514.000.000 -16.53%
2010 23.047.000.000 2.31%
2011 29.173.000.000 21%
2012 25.046.000.000 -16.48%
2013 21.926.000.000 -14.23%
2014 19.231.000.000 -14.01%
2015 17.693.000.000 -8.69%
2016 19.076.000.000 7.25%
2017 20.237.000.000 5.74%
2018 21.412.000.000 5.49%
2019 19.747.000.000 -8.43%
2020 14.066.000.000 -40.39%
2021 28.533.000.000 50.7%
2022 43.639.000.000 34.62%
2023 -3.212.000.000 1458.62%
2023 14.448.000.000 122.23%
2024 17.580.000.000 17.82%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Pfizer Inc. Gross Profit
Year Gross Profit Growth
1985 2.608.300.000
1986 2.902.700.000 10.14%
1987 3.184.900.000 8.86%
1988 3.559.800.000 10.53%
1989 3.816.300.000 6.72%
1990 4.371.400.000 12.7%
1991 4.993.500.000 12.46%
1992 5.469.800.000 8.71%
1993 5.963.900.000 8.28%
1994 6.654.700.000 10.38%
1995 8.231.300.000 19.15%
1996 9.560.000.000 13.9%
1997 10.732.000.000 10.92%
1998 11.939.000.000 10.11%
1999 14.218.000.000 16.03%
2000 25.515.000.000 44.28%
2001 27.225.000.000 6.28%
2002 28.328.000.000 3.89%
2003 35.356.000.000 19.88%
2004 44.975.000.000 21.39%
2005 42.773.000.000 -5.15%
2006 40.731.000.000 -5.01%
2007 37.179.000.000 -9.55%
2008 40.184.000.000 7.48%
2009 41.121.000.000 2.28%
2010 51.530.000.000 20.2%
2011 52.340.000.000 1.55%
2012 47.652.000.000 -9.84%
2013 41.998.000.000 -13.46%
2014 40.028.000.000 -4.92%
2015 39.203.000.000 -2.1%
2016 40.495.000.000 3.19%
2017 41.306.000.000 1.96%
2018 42.399.000.000 2.58%
2019 41.531.000.000 -2.09%
2020 33.216.000.000 -25.03%
2021 50.467.000.000 34.18%
2022 65.986.000.000 23.52%
2023 15.852.000.000 -316.26%
2023 33.542.000.000 52.74%
2024 39.932.000.000 16%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Pfizer Inc. Net Profit
Year Net Profit Growth
1985 579.700.000
1986 660.000.000 12.17%
1987 690.200.000 4.38%
1988 791.300.000 12.78%
1989 681.100.000 -16.18%
1990 801.200.000 14.99%
1991 722.100.000 -10.95%
1992 810.900.000 10.95%
1993 657.500.000 -23.33%
1994 1.298.400.000 49.36%
1995 1.572.900.000 17.45%
1996 1.929.000.000 18.46%
1997 2.213.000.000 12.83%
1998 3.351.000.000 33.96%
1999 3.179.000.000 -5.41%
2000 3.726.000.000 14.68%
2001 7.788.000.000 52.16%
2002 9.126.000.000 14.66%
2003 3.906.000.000 -133.64%
2004 11.356.000.000 65.6%
2005 8.079.000.000 -40.56%
2006 19.332.000.000 58.21%
2007 8.140.000.000 -137.49%
2008 8.104.000.000 -0.44%
2009 8.635.000.000 6.15%
2010 8.255.000.000 -4.6%
2011 10.007.000.000 17.51%
2012 14.568.000.000 31.31%
2013 22.001.000.000 33.78%
2014 9.133.000.000 -140.9%
2015 6.958.000.000 -31.26%
2016 7.214.000.000 3.55%
2017 21.306.000.000 66.14%
2018 11.151.000.000 -91.07%
2019 16.025.000.000 30.41%
2020 9.159.000.000 -74.96%
2021 21.979.000.000 58.33%
2022 31.372.000.000 29.94%
2023 -9.528.000.000 429.26%
2023 2.119.000.000 549.65%
2024 164.000.000 -1192.07%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Pfizer Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 1 0%
1997 1 0%
1998 1 0%
1999 1 0%
2000 1 0%
2001 1 100%
2002 1 0%
2003 1 0%
2004 2 100%
2005 1 0%
2006 3 50%
2007 1 -100%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 2 0%
2013 3 66.67%
2014 1 -200%
2015 1 0%
2016 1 0%
2017 4 66.67%
2018 2 -200%
2019 3 50%
2020 2 -100%
2021 4 66.67%
2022 6 40%
2023 -2 600%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Pfizer Inc. Free Cashflow
Year Free Cashflow Growth
1989 199.300.000
1990 313.000.000 36.33%
1991 253.800.000 -23.33%
1992 132.800.000 -91.11%
1993 628.800.000 78.88%
1994 817.000.000 23.04%
1995 1.125.100.000 27.38%
1996 1.293.000.000 12.99%
1997 686.000.000 -88.48%
1998 1.731.000.000 60.37%
1999 1.495.000.000 -15.79%
2000 4.004.000.000 62.66%
2001 7.060.000.000 43.29%
2002 8.425.000.000 16.2%
2003 9.098.000.000 7.4%
2004 13.739.000.000 33.78%
2005 12.627.000.000 -8.81%
2006 15.544.000.000 18.77%
2007 11.473.000.000 -35.48%
2008 16.537.000.000 30.62%
2009 15.382.000.000 -7.51%
2010 9.941.000.000 -54.73%
2011 18.580.000.000 46.5%
2012 15.727.000.000 -18.14%
2013 16.300.000.000 3.52%
2014 15.300.000.000 -6.54%
2015 13.016.000.000 -17.55%
2016 13.902.000.000 6.37%
2017 14.253.000.000 2.46%
2018 13.631.000.000 -4.56%
2019 9.994.000.000 -36.39%
2020 11.612.000.000 13.93%
2021 29.869.000.000 61.12%
2022 26.031.000.000 -14.74%
2023 2.646.000.000 -883.79%
2023 4.793.000.000 44.79%
2024 -2.418.000.000 298.22%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Pfizer Inc. Operating Cashflow
Year Operating Cashflow Growth
1989 655.800.000
1990 860.500.000 23.79%
1991 847.600.000 -1.52%
1992 807.000.000 -5.03%
1993 1.263.000.000 36.1%
1994 1.488.500.000 15.15%
1995 1.821.400.000 18.28%
1996 2.067.000.000 11.88%
1997 1.629.000.000 -26.89%
1998 2.929.000.000 44.38%
1999 3.056.000.000 4.16%
2000 6.195.000.000 50.67%
2001 9.263.000.000 33.12%
2002 10.183.000.000 9.03%
2003 11.739.000.000 13.25%
2004 16.340.000.000 28.16%
2005 14.733.000.000 -10.91%
2006 17.594.000.000 16.26%
2007 13.353.000.000 -31.76%
2008 18.238.000.000 26.78%
2009 16.587.000.000 -9.95%
2010 11.454.000.000 -44.81%
2011 20.240.000.000 43.41%
2012 17.054.000.000 -18.68%
2013 17.765.000.000 4%
2014 16.883.000.000 -5.22%
2015 14.512.000.000 -16.34%
2016 15.901.000.000 8.74%
2017 16.470.000.000 3.45%
2018 15.827.000.000 -4.06%
2019 12.588.000.000 -25.73%
2020 14.403.000.000 12.6%
2021 32.580.000.000 55.79%
2022 29.267.000.000 -11.32%
2023 3.456.000.000 -746.85%
2023 8.700.000.000 60.28%
2024 -1.781.000.000 588.49%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Pfizer Inc. Capital Expenditure
Year Capital Expenditure Growth
1989 456.500.000
1990 547.500.000 16.62%
1991 593.800.000 7.8%
1992 674.200.000 11.93%
1993 634.200.000 -6.31%
1994 671.500.000 5.55%
1995 696.300.000 3.56%
1996 774.000.000 10.04%
1997 943.000.000 17.92%
1998 1.198.000.000 21.29%
1999 1.561.000.000 23.25%
2000 2.191.000.000 28.75%
2001 2.203.000.000 0.54%
2002 1.758.000.000 -25.31%
2003 2.641.000.000 33.43%
2004 2.601.000.000 -1.54%
2005 2.106.000.000 -23.5%
2006 2.050.000.000 -2.73%
2007 1.880.000.000 -9.04%
2008 1.701.000.000 -10.52%
2009 1.205.000.000 -41.16%
2010 1.513.000.000 20.36%
2011 1.660.000.000 8.86%
2012 1.327.000.000 -25.09%
2013 1.465.000.000 9.42%
2014 1.583.000.000 7.45%
2015 1.496.000.000 -5.82%
2016 1.999.000.000 25.16%
2017 2.217.000.000 9.83%
2018 2.196.000.000 -0.96%
2019 2.594.000.000 15.34%
2020 2.791.000.000 7.06%
2021 2.711.000.000 -2.95%
2022 3.236.000.000 16.22%
2023 810.000.000 -299.51%
2023 3.907.000.000 79.27%
2024 637.000.000 -513.34%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Pfizer Inc. Equity
Year Equity Growth
1985 2.927.300.000
1986 3.415.300.000 14.29%
1987 3.882.400.000 12.03%
1988 4.301.100.000 9.73%
1989 4.559.900.000 5.68%
1990 5.120.700.000 10.95%
1991 5.060.700.000 -1.19%
1992 4.753.500.000 -6.46%
1993 3.904.800.000 -21.73%
1994 4.362.700.000 10.5%
1995 5.553.200.000 21.44%
1996 7.004.000.000 20.71%
1997 7.933.000.000 11.71%
1998 8.810.000.000 9.95%
1999 8.887.000.000 0.87%
2000 16.076.000.000 44.72%
2001 18.293.000.000 12.12%
2002 19.950.000.000 8.31%
2003 65.377.000.000 69.48%
2004 68.278.000.000 4.25%
2005 65.627.000.000 -4.04%
2006 71.432.000.000 8.13%
2007 65.124.000.000 -9.69%
2008 57.740.000.000 -12.79%
2009 90.446.000.000 36.16%
2010 88.265.000.000 -2.47%
2011 82.621.000.000 -6.83%
2012 81.678.000.000 -1.15%
2013 76.620.000.000 -6.6%
2014 71.622.000.000 -6.98%
2015 64.998.000.000 -10.19%
2016 59.840.000.000 -8.62%
2017 71.656.000.000 16.49%
2018 63.758.000.000 -12.39%
2019 63.446.000.000 -0.49%
2020 63.473.000.000 0.04%
2021 77.463.000.000 18.06%
2022 95.917.000.000 19.24%
2023 89.288.000.000 -7.42%
2023 97.204.000.000 8.14%
2024 87.975.000.000 -10.49%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Pfizer Inc. Assets
Year Assets Growth
1985 4.462.900.000
1986 5.163.700.000 13.57%
1987 6.922.600.000 25.41%
1988 7.637.600.000 9.36%
1989 8.324.800.000 8.25%
1990 9.052.000.000 8.03%
1991 9.634.600.000 6.05%
1992 9.590.100.000 -0.46%
1993 9.330.900.000 -2.78%
1994 11.098.500.000 15.93%
1995 12.729.300.000 12.81%
1996 14.667.000.000 13.21%
1997 15.336.000.000 4.36%
1998 18.302.000.000 16.21%
1999 20.574.000.000 11.04%
2000 33.510.000.000 38.6%
2001 39.153.000.000 14.41%
2002 46.356.000.000 15.54%
2003 116.775.000.000 60.3%
2004 123.684.000.000 5.59%
2005 117.565.000.000 -5.2%
2006 114.837.000.000 -2.38%
2007 115.268.000.000 0.37%
2008 111.148.000.000 -3.71%
2009 212.949.000.000 47.81%
2010 195.014.000.000 -9.2%
2011 188.002.000.000 -3.73%
2012 185.798.000.000 -1.19%
2013 172.101.000.000 -7.96%
2014 169.274.000.000 -1.67%
2015 167.460.000.000 -1.08%
2016 171.615.000.000 2.42%
2017 171.797.000.000 0.11%
2018 159.422.000.000 -7.76%
2019 167.488.000.000 4.82%
2020 154.229.000.000 -8.6%
2021 181.477.000.000 15.01%
2022 197.206.000.000 7.98%
2023 226.501.000.000 12.93%
2023 215.021.000.000 -5.34%
2024 216.193.000.000 0.54%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Pfizer Inc. Liabilities
Year Liabilities Growth
1985 1.535.600.000
1986 1.748.400.000 12.17%
1987 3.040.200.000 42.49%
1988 3.336.500.000 8.88%
1989 3.764.900.000 11.38%
1990 3.931.300.000 4.23%
1991 4.573.900.000 14.05%
1992 4.836.600.000 5.43%
1993 5.426.100.000 10.86%
1994 6.735.800.000 19.44%
1995 7.176.100.000 6.14%
1996 7.663.000.000 6.35%
1997 7.403.000.000 -3.51%
1998 9.492.000.000 22.01%
1999 11.687.000.000 18.78%
2000 17.434.000.000 32.96%
2001 20.860.000.000 16.42%
2002 26.406.000.000 21%
2003 51.398.000.000 48.62%
2004 55.406.000.000 7.23%
2005 51.938.000.000 -6.68%
2006 43.479.000.000 -19.46%
2007 50.144.000.000 13.29%
2008 53.408.000.000 6.11%
2009 122.503.000.000 56.4%
2010 106.749.000.000 -14.76%
2011 105.381.000.000 -1.3%
2012 104.120.000.000 -1.21%
2013 95.481.000.000 -9.05%
2014 97.652.000.000 2.22%
2015 102.462.000.000 4.69%
2016 111.775.000.000 8.33%
2017 100.141.000.000 -11.62%
2018 95.664.000.000 -4.68%
2019 104.042.000.000 8.05%
2020 90.756.000.000 -14.64%
2021 104.014.000.000 12.75%
2022 101.289.000.000 -2.69%
2023 137.213.000.000 26.18%
2023 117.817.000.000 -16.46%
2024 128.218.000.000 8.11%

Pfizer Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
9.82
Net Income per Share
-0.46
Price to Earning Ratio
-63.8x
Price To Sales Ratio
2.98x
POCF Ratio
20.68
PFCF Ratio
34.42
Price to Book Ratio
1.89
EV to Sales
4.19
EV Over EBITDA
20.42
EV to Operating CashFlow
29.13
EV to FreeCashFlow
48.48
Earnings Yield
-0.02
FreeCashFlow Yield
0.03
Market Cap
165,55 Bil.
Enterprise Value
233,18 Bil.
Graham Number
12.63
Graham NetNet
-18.37

Income Statement Metrics

Net Income per Share
-0.46
Income Quality
-3.12
ROE
-0.03
Return On Assets
-0.01
Return On Capital Employed
0.03
Net Income per EBT
0.62
EBT Per Ebit
-0.77
Ebit per Revenue
0.1
Effective Tax Rate
0.38

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.19
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.58
Operating Profit Margin
0.1
Pretax Profit Margin
-0.07
Net Profit Margin
-0.05

Dividends

Dividend Yield
0.06
Dividend Yield %
5.72
Payout Ratio
-3.62
Dividend Per Share
1.67

Operating Metrics

Operating Cashflow per Share
1.41
Free CashFlow per Share
0.85
Capex to Operating CashFlow
0.4
Capex to Revenue
0.06
Capex to Depreciation
0.48
Return on Invested Capital
0.02
Return on Tangible Assets
-0.03
Days Sales Outstanding
98.97
Days Payables Outstanding
79.27
Days of Inventory on Hand
177.71
Receivables Turnover
3.69
Payables Turnover
4.6
Inventory Turnover
2.05
Capex per Share
0.56

Balance Sheet

Cash per Share
1,25
Book Value per Share
15,52
Tangible Book Value per Share
-7.36
Shareholders Equity per Share
15.48
Interest Debt per Share
12.64
Debt to Equity
0.78
Debt to Assets
0.32
Net Debt to EBITDA
5.92
Current Ratio
0.86
Tangible Asset Value
-41,71 Bil.
Net Current Asset Value
-90,39 Bil.
Invested Capital
142648000000
Working Capital
-5,99 Bil.
Intangibles to Total Assets
0.6
Average Receivables
15,15 Bil.
Average Payables
5,35 Bil.
Average Inventory
11169500000
Debt to Market Cap
0.41

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Pfizer Inc. Dividends
Year Dividends Growth
2010 0
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 100%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 100%
2019 1 0%
2020 2 0%
2021 2 0%
2022 2 0%
2023 2 0%
2024 1 0%

Pfizer Inc. Profile

About Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

CEO
Dr. Albert Bourla D.V.M., Ph.
Employee
88.000
Address
235 East 42nd Street
New York, 10017

Pfizer Inc. Executives & BODs

Pfizer Inc. Executives & BODs
# Name Age
1 Mr. Andreas J. Panayiotou
Global Chief Marketing Officer
70
2 Ms. Payal Sahni Becher
Chief People Experience Officer & Executive Vice President
70
3 Ms. Francesca M. DeMartino
Chief Investor Relations Officer
70
4 Dr. Albert Bourla D.V.M., Ph.D.
Chairman of the Board & Chief Executive Officer
70
5 Dr. Mikael Dolsten M.D., Ph.D.
Chief Scientific Officer and President of Research & Development
70
6 Ms. Lidia L. Fonseca
Executive Vice President and Chief Digital & Technology Officer
70
7 Mr. Douglas M. Lankler
Executive Vice President & General Counsel
70
8 Ms. Jennifer B. Damico
Senior Vice President, Controller & Principal Accounting Officer
70
9 Mr. Rady A. Johnson
Executive Vice President and Chief Compliance, Quality & Risk Officer
70
10 Mr. David M. Denton
Chief Financial Officer & Executive Vice President
70

Pfizer Inc. Competitors

Pfizer Inc. Logo
Pfizer Inc.

PFE.DE

(2.0)
Microsoft Corporation Logo
Microsoft Corporation

MSF.F

(3.2)
Moderna, Inc. Logo
Moderna, Inc.

0QF.F

(1.2)